ArticleJournal of pediatric surgery2026
Economic evaluation of Hirschsprung disease testing strategies for children with medically-refractory chronic constipation: A cost-effectiveness analysis.
Article in Journal of pediatric surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundEarly and accurate diagnosis of Hirschsprung disease (HSCR) prevents life-threatening complications, improves patient outcomes, and reduces healthcare utilization. Contrast enema (CE), anorectal manometry (AMAN), and rectal biopsy (RB) are commonly used diagnostic tests, with RB being the gold standard. However, the most cost-effective initial diagnostic strategy remains unclear.
methodsA decision-analytic model was used to compare CE-first, AMAN-first, and RB-first strategies for the evaluation of HSCR in children between 1 and 18 years of age presenting to specialty care for chronic constipation. The model incorporated diagnostic test performance, disease prevalence, and timing of surgical intervention over a three-year time horizon. Health utilities were estimated by mapping published Pediatric Quality of Life Inventory (PedsQL) scores to Child Health Utility 9D (CHU9D) values. Costs were averaged from institutional data. Willingness-to-pay (WTP) threshold was set at $50,000 per quality-adjusted life year (QALY). Outcomes included costs, QALYs, net monetary benefit (NMB), and incremental cost-effectiveness ratios (ICERs). Deterministic and probabilistic sensitivity analyses were performed.
resultsCE-first emerged as the most cost-effective diagnostic strategy at a WTP of $50,000/QALY. RB-first provided greater effectiveness but at higher cost and was not cost-effective at the base-case threshold. RB-first became preferred when HSCR prevalence exceeded 29.2% and when the sensitivity of the test exceeded 97.8%. AMAN-first was least cost-effective and became preferred only when its sensitivity exceeded 90.5%.
conclusionsIn the evaluation of children over 1 year of age presenting to specialty care with suspected HSCR, CE was the most cost-effective initial strategy in most scenarios. These findings provide economic insight to guide clinical decision-making for the diagnostic testing of HSCR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.